Results for tag: "Self Administered Parenteral"

In the context of healthcare services, the self-administered parenteral market consists of medications and therapies that patients can inject themselves without the need for professional assistance at a medical facility. This includes treatments for chronic diseases, biologics, and vaccines administered through methods such as syringes, pens, and autoinjectors. The market is driven by the increasing prevalence of chronic illnesses, advancements in drug delivery technologies, an emphasis on patient-centric care, and the need for cost-effective treatment alternatives. Self-administration devices are designed to be user-friendly, ensuring safety, accuracy, and adherence to medication regimens. These devices improve the quality of life for patients by allowing greater autonomy, convenience, and flexibility in managing their health conditions. The healthcare industry supports this transition through patient education and support services to ensure correct usage of the devices. Several companies have a notable presence in the self-administered parenteral market. These include major pharmaceutical and biotechnology firms such as Amgen Inc., AbbVie Inc., and Pfizer Inc. Medical device manufacturers such as Becton, Dickinson and Company (BD), and autoinjector specialists like Mylan (now part of Viatris Inc.) also contribute to the development and supply of self-administration products. These companies actively engage in research and development to improve existing technologies and to ensure a wider range of medications can be safely and effectively self-administered. Show Less Read more